BMRN ends Voxzogo development for Noonan syndrome as the drug faces new competition and pursues other growth opportunities.

BioMarin Stops Voxzogo Development for Noonan Syndrome

BMRN turns a competitive threat into a royalty stream as Ascendis pays royalties on Yuviwel sales, reshaping the economics of competition.

How BioMarin Turned a Competitive Threat Into a Royalty-Bearing Asset

The following companies are expected to report earnings prior to market open on 08/13/2026.  Visit our Earnings Calendar for a full list of expected earnings releases.Brookfield Corporation (BN)is reporting for the quarter ending June 30, 2026. The real estate company's consensus

Pre-Market Earnings Report for August 13, 2026 :  BN, JD, TPR, ASND, AIT, MSGS, BIRK, GDS, ONDS, CLBT, YETI, BLSH

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.

Ascendis Pharma A/S News